Relief Therapeutics slumps as U.S. DSMB recommends to cease COVID drug study

MindMaze Therapeutics Holding SA

27/05/2022 10:03

** Relief Therapeutics  RLFB.S  sinks 32% after it said on
Thursday https://www.relieftherapeutics.com/newsblog-detail/?newsID=2267875
 the Data Safety Monitoring Board (DSMB) of the U.S. National
Institutes of Health recommended that studies with aviptadil in
critical COVID-19 be stopped
    ** "The independent DSMB overseeing the ACTIV-3b (TESICO)
study determined that evaluation of aviptadil should cease due
to futility," the company says
    ** The study is run in collaboration with Relief
Therapeutics' U.S. partner NRx  NRXP.O 
    ** Shares of Relief Therapeutics are at their lowest in 1.8
years and on track for the worst day since February 2021
    ** Including today's fall, the stock has dropped 38% YTD

 (Reporting by Tristan Chabba)
 ((Tristan.chabba@thomsonreuters.com))